Individuals that are obtaining cyclosporine, tacrolimus or other brokers to stop graft-vs .-host sickness put up bone marrow transplant aren't qualified for this demoElimusertib treatment displays that a development-free survival advantage in a subset of preclinical pediatric strong tumors models when compared with SoC procedure. A, Illustration on